Neuropathic Pain
Conditions
Keywords
NMDA (N-Methyl-D-Aspartate) antagonists, ketamine, memantine, dextromethorphan, Neuropathic pain
Brief summary
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity. In clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. It will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.
Detailed description
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity. In clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. It will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.
Interventions
DRUGDextromethorphan (drug used like antitussive)
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
DRUGMemantine (drug used in Alzheimer's disease)
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Sponsors
University Hospital, Clermont-Ferrand
Dr Malou Navez, Pain Clinic, Saint-Etienne Hopital
Dr Marc Sorel, Pain Clinic, Nemours Hospital
Dr Anne-Margot Duclot, Pain Clinic, Paris Rotschild Hospital
Dr Monique Belon, Pain Clinic, Aurillac Hospital
Dr Marie-Christine Crosmary/Dr Renato Colamarino, Pain Clinic, Vichy Hospital
Dr Mohamed El Ayadi, Pain Clinic, Issoire Hospital
Dr Géraldine Brumauld de Montgazon, Pain Clinic, La Rochelle Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \> 18 years old * patient suffering chronic neuropathic pain * All chronic pain is retained except central or diabetic pain * Answering patient at ketamine in pain treatment by investigator, and having already received ketamine * Patient who completed before ketamine the following evaluation : DN4, QCD, QDSA, PGIC questionnaires, HAD scale, Leed's sleep evaluation and SF36. * Patient who completed at the end of treatment the following evaluation : numerical scale and PGIC * Sufficient cooperation and understanding to comply to the requirements of study * Acceptance to give a written concert * Affiliation at system of French social security * Inscription or acceptation of inscription at national register of voluntaries participant at research
Exclusion criteria
* Against-indication at memantine or dextromethorphan administration : hypersensitivity at active substance or excipients, hypertension, antecedent cerebrovascular accident, severe cardiac insufficiency * Patient with medical or surgical antecedents * Patient with progressive disease at balance of inclusion * Patient treated by an IMAO * Woman in childbearing age not using effective contraceptive method, pregnant or lactating woman * Patient who participated in another clinical trial, located in exclusion period or received benefits \> 4500 euros during 12 months before the beginning of trial * Patient with cooperation and understanding insufficiency to comply to the requirements of protocol * Patient with social protection * No affiliation at system of French social security
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure of pain by numerical scale | at Day 30 |
Secondary
| Measure | Time frame |
|---|---|
| Measure of pain by numerical scale | at day 60 and at day 90 |
| Patient Global Impression if Change (PGIC) | at day 30, at day 60 and at day 90 |
| Leed's slip questionnaire | at day 30, at day 60 and at day 90 |
| Questionnaire of quality of life SF 36 | at day 30, at day 60 and at day 90 |
| DN4 scale | at day 30, at day 60 and at day 90 |
| Neuropathic Pain Symptoms Inventory (NPSI) | at day 30, at day 60 and at day 90 |
| Saint-Antoine questionnaire (QDSA) | at day 30, at day 60 and at day 90 |
| HAD scale | at day 30, at day 60 and at day 90 |
| Questionnaire of identification of pain (QCD) | at day 30, at day 60 and at day 90 |
| Evaluation of cognitive impact (Cantab, Cambridge) | at day 30, at day 60 and at day 90 |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORGisèle PICKERING
University Hospital, Clermont-Ferrand
Outcome results
None listed